| scholarly article | Q13442814 |
| P50 | author | C P Reynolds | Q67015887 |
| P2093 | author name string | Hua Fang | |
| Yves A DeClerck | |||
| Ondrej Kalous | |||
| Vanessa Maldonado | |||
| Theresa M Harned | |||
| P2860 | cites work | Bid, a Bcl2 interacting protein, mediates cytochrome c release from mitochondria in response to activation of cell surface death receptors | Q24310559 |
| Anti-GD2 antibody with GM-CSF, interleukin-2, and isotretinoin for neuroblastoma | Q24602657 | ||
| Bcl-2 inhibitors: targeting mitochondrial apoptotic pathways in cancer therapy | Q24635408 | ||
| Long-term results for children with high-risk neuroblastoma treated on a randomized trial of myeloablative therapy followed by 13-cis-retinoic acid: a children's oncology group study | Q24658339 | ||
| Short tandem repeat profiling provides an international reference standard for human cell lines | Q27910569 | ||
| Bid-deficient mice are resistant to Fas-induced hepatocellular apoptosis | Q28511080 | ||
| Caspase cleaved BID targets mitochondria and is required for cytochrome c release, while BCL-XL prevents this release but not tumor necrosis factor-R1/Fas death | Q28586301 | ||
| Quantitative analysis of dose-effect relationships: the combined effects of multiple drugs or enzyme inhibitors | Q29547463 | ||
| An inhibitor of Bcl-2 family proteins induces regression of solid tumours | Q29547595 | ||
| Distinct BH3 domains either sensitize or activate mitochondrial apoptosis, serving as prototype cancer therapeutics | Q29620467 | ||
| 'Seed' analysis of off-target siRNAs reveals an essential role of Mcl-1 in resistance to the small-molecule Bcl-2/Bcl-XL inhibitor ABT-737. | Q33266778 | ||
| Navitoclax, a targeted high-affinity inhibitor of BCL-2, in lymphoid malignancies: a phase 1 dose-escalation study of safety, pharmacokinetics, pharmacodynamics, and antitumour activity | Q33392920 | ||
| Phase I study of Navitoclax (ABT-263), a novel Bcl-2 family inhibitor, in patients with small-cell lung cancer and other solid tumors | Q33393931 | ||
| Molecular biology of neuroblastoma | Q33773346 | ||
| Treatment of high-risk neuroblastoma with intensive chemotherapy, radiotherapy, autologous bone marrow transplantation, and 13-cis-retinoic acid. Children's Cancer Group | Q33876841 | ||
| BH3 mimetic ABT-737 potentiates TRAIL-mediated apoptotic signaling by unsequestering Bim and Bak in human pancreatic cancer cells | Q34168023 | ||
| Cleavage of CAD inhibitor in CAD activation and DNA degradation during apoptosis | Q34451533 | ||
| BCL-2 family antagonists for cancer therapy | Q34891196 | ||
| Retinoid therapy of high-risk neuroblastoma. | Q35184993 | ||
| Chronic lymphocytic leukemia requires BCL2 to sequester prodeath BIM, explaining sensitivity to BCL2 antagonist ABT-737. | Q35250940 | ||
| DIMSCAN: a microcomputer fluorescence-based cytotoxicity assay for preclinical testing of combination chemotherapy. | Q36131755 | ||
| BCL-2: found bound and drugged! | Q36252675 | ||
| Caspase-8 and bid: caught in the act between death receptors and mitochondria | Q37835913 | ||
| Drug resistance patterns of human neuroblastoma cell lines derived from patients at different phases of therapy. | Q39481908 | ||
| Increase of ceramide and induction of mixed apoptosis/necrosis by N-(4-hydroxyphenyl)- retinamide in neuroblastoma cell lines | Q39511962 | ||
| A fluorescence microplate cytotoxicity assay with a 4-log dynamic range that identifies synergistic drug combinations | Q39789949 | ||
| Mechanism of synergy of N-(4-hydroxyphenyl)retinamide and ABT-737 in acute lymphoblastic leukemia cell lines: Mcl-1 inactivation. | Q39993903 | ||
| The Bcl-2/Bcl-XL family inhibitor ABT-737 sensitizes ovarian cancer cells to carboplatin | Q40041107 | ||
| Targeting BCL-2 family proteins to overcome drug resistance in non-small cell lung cancer | Q40096307 | ||
| Activity of vincristine, L-ASP, and dexamethasone against acute lymphoblastic leukemia is enhanced by the BH3-mimetic ABT-737 in vitro and in vivo. | Q40126446 | ||
| Improved oral delivery of N-(4-hydroxyphenyl)retinamide with a novel LYM-X-SORB organized lipid complex | Q40132570 | ||
| Influence of Bcl-2 family members on the cellular response of small-cell lung cancer cell lines to ABT-737. | Q40174205 | ||
| Loss of p53 function confers high-level multidrug resistance in neuroblastoma cell lines | Q40785878 | ||
| Cancer statistics, 1999. | Q40817780 | ||
| Mitochondrial proliferation and paradoxical membrane depolarization during terminal differentiation and apoptosis in a human colon carcinoma cell line | Q41098628 | ||
| Reduced expression of proapoptotic gene BAX is associated with poor response rates to combination chemotherapy and shorter survival in women with metastatic breast adenocarcinoma | Q43821574 | ||
| Phase I trial and pharmacokinetics of fenretinide in children with neuroblastoma. | Q44471521 | ||
| Mcl-1 down-regulation potentiates ABT-737 lethality by cooperatively inducing Bak activation and Bax translocation | Q44926251 | ||
| Phase I trial of oral fenretinide in children with high-risk solid tumors: a report from the Children's Oncology Group (CCG 09709). | Q46068154 | ||
| Differentiation of neuroblastoma enhances Bcl-2 expression and induces alterations of apoptosis and drug resistance | Q46093621 | ||
| Determination of subcutaneous tumor size in athymic (nude) mice | Q46296687 | ||
| Retinoic-acid-resistant neuroblastoma cell lines show altered MYC regulation and high sensitivity to fenretinide. | Q46947417 | ||
| Generalized Equations for the Analysis of Inhibitions of Michaelis-Menten and Higher-Order Kinetic Systems with Two or More Mutually Exclusive and Nonexclusive Inhibitors | Q52739596 | ||
| Characterization of human neuroblastoma cell lines established before and after therapy. | Q52834184 | ||
| A novel Bcl-2/Bcl-X(L)/Bcl-w inhibitor ABT-737 as therapy in multiple myeloma. | Q53595735 | ||
| Differential effects of N-(4-hydroxyphenyl)retinamide and retinoic acid on neuroblastoma cells: apoptosis versus differentiation | Q72532669 | ||
| Neuroblastoma cell apoptosis induced by the synthetic retinoid N-(4-hydroxyphenyl)retinamide | Q72721420 | ||
| Caspase-8 and apoptosis-inducing factor mediate a cytochrome c-independent pathway of apoptosis in human colon cancer cells induced by the dietary phytochemical chlorophyllin | Q73154723 | ||
| P433 | issue | 22 | |
| P407 | language of work or name | English | Q1860 |
| P304 | page(s) | 7093-7104 | |
| P577 | publication date | 2011-09-20 | |
| P1433 | published in | Clinical Cancer Research | Q332253 |
| P1476 | title | Synergistic activity of fenretinide and the Bcl-2 family protein inhibitor ABT-737 against human neuroblastoma | |
| P478 | volume | 17 |
| Q90590054 | A direct comparison of selective BH3-mimetics reveals BCL-XL, BCL-2 and MCL-1 as promising therapeutic targets in neuroblastoma |
| Q35781382 | A transcriptomic signature mediated by HOXA9 promotes human glioblastoma initiation, aggressiveness and resistance to temozolomide |
| Q38982534 | Caspase-dependent Mcl-1 cleavage and effect of Mcl-1 phosphorylation in ABT-737-induced apoptosis in human acute lymphoblastic leukemia cell lines. |
| Q28485302 | Cell-based small-molecule compound screen identifies fenretinide as potential therapeutic for translocation-positive rhabdomyosarcoma |
| Q91651290 | Combination of fenretinide and ABT-263 induces apoptosis through NOXA for head and neck squamous cell carcinoma treatment |
| Q37375377 | Combination of fenretinide and selenite inhibits proliferation and induces apoptosis in ovarian cancer cells |
| Q38944587 | Combining a BCL2 inhibitor with the retinoid derivative fenretinide targets melanoma cells including melanoma initiating cells |
| Q40185074 | Mild thermotolerance induced at 40 °C protects cells against hyperthermia-induced pro-apoptotic changes in Bcl-2 family proteins. |
| Q39347735 | Mitochondrial Bcl-2 family dynamics define therapy response and resistance in neuroblastoma |
| Q38710659 | P450 inhibitor ketoconazole increased the intratumor drug levels and antitumor activity of fenretinide in human neuroblastoma xenograft models. |
| Q39268126 | RNA interference screening identifies a novel role for autocrine fibroblast growth factor signaling in neuroblastoma chemoresistance |
| Q39106943 | Reversal of lung cancer multidrug resistance by pH-responsive micelleplexes mediating co-delivery of siRNA and paclitaxel |
| Q39944723 | The Wnt Target Protein Peter Pan Defines a Novel p53-independent Nucleolar Stress-Response Pathway |
| Q28487756 | The sensitivity of diffuse large B-cell lymphoma cell lines to histone deacetylase inhibitor-induced apoptosis is modulated by BCL-2 family protein activity |
| Q38876333 | Thymosin-β4 is a determinant of drug sensitivity for Fenretinide and Vorinostat combination therapy in neuroblastoma. |
| Q42117299 | Understanding sensitivity to BH3 mimetics: ABT-737 as a case study to foresee the complexities of personalized medicine |
| Q49907165 | p53-independent Noxa induction by cisplatin is regulated by ATF3/ATF4 in head and neck squamous cell carcinoma cells |
Search more.